T1	intervention 29 40	PEG-rhG-CSF
T2	control 48 55	rhG-CSF
T3	eligibility 59 140	breast cancer patients receiving multiple cycles of myelosuppressive chemotherapy
T4	location 267 274	China's
T5	total-participants 529 532	569
T8	outcome-Measure 842 874	incidence of febrile neutropenia
T9	outcome-Measure 884 890	safety
T10	outcome 1337 1374	incidence of all-grade adverse events
T14	outcome 1536 1586	incidence of grade 3/4 drug-related adverse events
T16	iv-bin-abs 1591 1592	2
T17	intervention-participants 1593 1596	187
T18	iv-bin-abs 1606 1607	1
T19	intervention-participants 1608 1611	188
T21	cv-bin-abs 1625 1626	8
T22	control-participants 1627 1630	194
T23	cv-bin-percent 1632 1637	4.12%
T11	iv-bin-abs 1388 1391	129
T24	iv-bin-percent 1393 1399	68.98%
T12	iv-bin-abs 1402 1405	142
T25	iv-bin-percent 1407 1413	75.53%
T13	cv-bin-abs 1420 1423	160
T26	cv-bin-percent 1425 1431	82.47%
T15	iv-bin-percent 1598 1603	1.07%
T20	iv-bin-percent 1613 1618	0.53%
T6	outcome-Measure 674 736	incidence and duration of grade 3/4 neutropenia during cycle 1
